Payment overview · 2025
General Payments
$1,021.90
54 reported records · 20 companies
Healthcare provider profile · identity verified
Saba Masood Salahuddin
Allopathic & Osteopathic Physicians|Internal Medicine · MYRTLE BEACH, SC · NPI 1821595042
Verified facts
What the public records show
CMS Open Payments records show Saba Masood Salahuddin received $1,021.90 in general payments during 2025 across 54 reported records.
Novo Nordisk Inc accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $206.06 | 20.2% | 9 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $153.40 | 15.0% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.17 | 13.6% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.72 | 5.9% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $54.54 | 5.3% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $50.81 | 5.0% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $44.28 | 4.3% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $38.26 | 3.7% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $34.52 | 3.4% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $34.39 | 3.4% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $31.28 | 3.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.60 | 2.9% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $28.50 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.04 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.79 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.08 | 1.8% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $16.77 | 1.6% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $15.52 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.69 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.48 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,021.90 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $153.40 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.03 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.03 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $76.41 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.72 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $54.54 | 3 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $50.81 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.62 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.62 | 4 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $44.28 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $34.52 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $34.39 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $11.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
85 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 881 | 286 |
| Amlodipine Besylate | Amlodipine Besylate | 664 | 225 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 147 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 377 | 123 |
| Hydrochlorothiazide | Hydrochlorothiazide | 365 | 122 |
| Lisinopril | Lisinopril | 348 | 109 |
| Omeprazole | Omeprazole | 345 | 113 |
| Losartan Potassium | Losartan Potassium | 332 | 110 |
| Metformin Hcl | Metformin Hcl | 283 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 189 | 63 |
| Meloxicam | Meloxicam | 165 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 48 |
| Trazodone Hcl | Trazodone Hcl | 145 | 48 |
| Gabapentin | Gabapentin | 142 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 45 |
| Simvastatin | Simvastatin | 139 | 45 |
| Metformin Hcl Er | Metformin Hcl | 133 | 50 |
| Ozempic | Semaglutide | 129 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 34 |
| Sertraline Hcl | Sertraline Hcl | 122 | 38 |
| Glipizide Er | Glipizide | 109 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 39 |
| Montelukast Sodium | Montelukast Sodium | 92 | 32 |
| Atenolol | Atenolol | 90 | 28 |
| Synthroid | Levothyroxine Sodium | 85 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 31 |
| Carvedilol | Carvedilol | 71 | 24 |
| Alendronate Sodium | Alendronate Sodium | 70 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 21 |
| Famotidine | Famotidine | 65 | 20 |
| Potassium Chloride | Potassium Chloride | 62 | 21 |
| Repatha Sureclick | Evolocumab | 61 | 14 |
| Furosemide | Furosemide | 60 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 15 |
| Celecoxib | Celecoxib | 52 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 18 |
| Valacyclovir | Valacyclovir Hcl | 49 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 18 |
| Allopurinol | Allopurinol | 44 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 35 |
| Finasteride | Finasteride | 40 | 14 |
| Azithromycin | Azithromycin | 39 | 36 |
| Eliquis | Apixaban | 38 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 12 |
| Ibuprofen | Ibuprofen | 38 | 11 |
| Meclizine Hcl | Meclizine Hcl | 37 | 17 |
| Ezetimibe | Ezetimibe | 36 | 17 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 11 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 16 |
| Prednisone | Prednisone | 21 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,021.90 · 54 records | Novo Nordisk Inc | ABRYSVO, ACTHAR, AIRSUPRA, BREZTRI, Bimzelx, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, INJECTAFER, ISTURISA, KRYSTEXXA, Kerendia, LEQVIO, OTEZLA, Ozempic, PREVNAR 20, Paradise Ultrasound Renal Denervation System, QULIPTA, QUTENZA, REPATHA, REZDIFFRA, Rybelsus, TREMFYA, TZIELD, Tymlos, UBRELVY, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error